Generic Name and Formulations:
Vilazodone HCl 10mg, 20mg, 40mg; tabs.
Indications for VIIBRYD:
Major depressive disorder.
Take with food. Initially 10mg once daily for 7 days, then 20mg once daily for 7 days, then increase to 40mg once daily. Concomitant strong CYP3A4 inhibitors: max 20mg once daily. Concomitant strong CYP3A4 inducers for >14 days: consider increasing dose up to 2-fold over 1–2 weeks; max 80mg daily. Readjust to original level when CYP3A4 inhibitors or inducers (in 14 days) are discontinued.
During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of vilazodone. Concomitant linezolid or IV methylene blue.
Suicidal thoughts and behaviors.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. Increased risk of bleeding. History of mania/hypomania. Seizure disorder. Angle-closure glaucoma. Volume depleted. Avoid abrupt disruption. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Pregnancy; effects on neonate exposed in 3rd trimester (see full labeling). Nursing mothers.
Selective serotonin reuptake inhibitor + 5-HT1A receptor partial agonist.
See Contraindications. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, warfarin (monitor), other anticoagulants. Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, voriconazole); see Adult. Antagonized by strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin); see Adult. Monitor digoxin. Caution with other highly protein-bound drugs.
Diarrhea, nausea, vomiting, insomnia; hyponatremia/SIADH (esp. in elderly).
Tabs—30; Patient Starter Kit (7x10mg tabs + 7x20mg tabs + 16x40mg tabs; 7x10mg tabs + 23x20mg tabs)—30
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis